BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19394048)

  • 1. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease.
    Omari T; Lundborg P; Sandström M; Bondarov P; Fjellman M; Haslam R; Davidson G
    J Pediatr; 2009 Aug; 155(2):222-8. PubMed ID: 19394048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
    López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
    Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):530-7. PubMed ID: 18030229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distension during gastroesophageal reflux: effects of acid inhibition and correlation with symptoms.
    Tipnis NA; Rhee PL; Mittal RK
    Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G469-74. PubMed ID: 17556589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
    Junghard O; Hassan-Alin M; Hasselgren G
    Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study.
    Li J; Zhao J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
    Clin Ther; 2006 Mar; 28(3):419-27. PubMed ID: 16750456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
    Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
    Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
    Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
    Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study.
    Bajbouj M; Becker V; Phillip V; Wilhelm D; Schmid RM; Meining A
    Digestion; 2009; 80(2):112-8. PubMed ID: 19641320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
    Omari TI; Haslam RR; Lundborg P; Davidson GP
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
    Gold BD; Gunasekaran T; Tolia V; Wetzler G; Conter H; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):520-9. PubMed ID: 18030228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
    Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
    Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
    Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
    Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26121346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative administration of esomeprazole has no influence on frequency of refluxes.
    Jeske HC; Borovicka J; von Goedecke A; Tiefenthaler W; Hohlrieder M; Heidegger T; Benzer A
    J Clin Anesth; 2008 May; 20(3):191-5. PubMed ID: 18502362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.
    Katz PO; Castell DO; Chen Y; Andersson T; Sostek MB
    Aliment Pharmacol Ther; 2004 Aug; 20(4):399-406. PubMed ID: 15298633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
    DelGaudio JM; Waring JP
    Laryngoscope; 2003 Apr; 113(4):598-601. PubMed ID: 12671413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
    Franke A; Hepp C; Harder H; Beglinger C; Singer MV
    Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.